TP53 and acute myeloid leukemia: Based on the 2022 ICC, 74.7% of the patients were assigned to the MDS group, including MDS with deletion-5q (MDS-del(5q), n = 4, 0.6%), MDS with mutated SF3B1 (MDS-SF3B1, n = 52, 8.0%), MDS, not otherwise specified with single lineage dysplasia (MDS, NOS with SLD, n = 111, 17.1%), or multi-lineage dysplasia (MDS, NOS with MLD, n = 152, 23.4%), MDS with excess blasts (MDS-EB, n = 141, 21.7%), and MDS with mutated TP53 (n = 25, 3.9%), and 25.3% of the patients were reassigned to the MDS/AML group.